Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 2, 2006, Pages 380-386

  Pea, Federico ^a   Poz, Donatella ^a   Viale, Pierluigi ^a   Pavan, Federica ^a   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Critically ill patients; Fluoroquinolones; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL CARE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LOGLINEAR MODEL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; PHARMACODYNAMICS; RELIABILITY; RETROSPECTIVE STUDY;

ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; CRITICAL ILLNESS; DRUG MONITORING; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 33748049790     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl226     Document Type: Article

References (32)

1. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 Suppl 3: S233-7.
2. MacGowan AP. Role of pharmacokinetics and pharmacodynamics: Does the dose matter? Clin Infect Dis 2001; 33 Suppl 3: S238-9.
3. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003; 9: 1-9.
4. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl 2: 29-36.
5. Rodvold KA, Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001; 21: 233-52S.
6. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother 2003; 37: 1287-98.
7. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: Human trials. Ann Pharmacother 2003; 37: 1478-88.
8. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
9. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA 1998; 279: 125-9.
10. Echols RM. The selection of appropriate dosages for intravenous ciprofloxacin. J Antimicrob Chemother 1993; 31: 783-7.
11. Bauernfeind A. Questioning dosing regimens of ciprofloxacin. J Antimicrob Chemother 1993; 31: 789-98.
12. Jones EM, McMullin CM, Hedges AJ et al. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: The effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997; 40: 121-4.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
14. Mack G. Improved high-performance liquid chromatographic determination of ciprofloxacin and its metabolites in human specimens. J Chromatogr 1992; 582: 263-7.
15. Pea F, Pavan F, Nascimben E et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother 2003; 47: 3104-8.
16. Blaser J, Stone BB, Groner MC et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60.
17. Lipman J, Scribante J, Gous AG et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. The Baragwanath Ciprofloxacin Study Group. Antimicrob Agents Chemother 1998; 42: 2235-9.
18. Shah A, Lettieri J, Nix D et al. Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother 1995; 39: 1003-6.
19. Gallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol 1996; 42: 632-4.
20. Overholser BR, Kays MB, Forrest A et al. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol 2004; 44: 1012-22.
21. Ramon J, Ben-Haim M, Shabtai M et al. Transepithelial intestinal excretion of ciprofloxacin in humans. Clin Infect Dis 2001; 32: 822-3.
22. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34.
23. Drusano GL, Weir M, Forrest A et al. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother 1987; 31: 860-4.
24. Gasser TC, Ebert SC, Graversen PH et al. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother 1987; 31: 709-12.
25. Kowalsky SF, Echols M, Schwartz MT et al. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin Nephrol 1993; 39: 53-8.
26. MacGowan AP, White LO, Brown NM et al. Serum ciprofloxacin concentrations in patients with severe sepsis being treated with ciprofloxacin 200 mg i.v. bd irrespective of renal function. J Antimicrob Chemother 1994; 33: 1051-4.
27. Dautrey S, Rabbaa L, Laouari D et al. Influence of renal failure on intestinal clearance of ciprofloxacin in rats. Antimicrob Agents Chemother 1999; 43: 678-80.
28. Gesu GP, Marchetti F, Piccoli L et al. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrob Agents Chemother 2003; 47: 816-9.
29. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 2004; 48: 2464-70.
30. Zelenitsky S, Ariano R, Harding G et al. Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother 2005; 49: 4009-14.
31. Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005; 40 Suppl 2: S105-14.
32. Pea F, Milaneschi R, Baraldo M et al. Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring. Ther Drug Monit 2000; 22: 386-91.